116 related articles for article (PubMed ID: 9856346)
1. Cloning and analysis of the Epstein-Barr virus glycoprotein 350 genes.
Chang SH; Kim SH; Lee WK; Kim HJ; Choi SH; Park JH; Jang HS; Chung GH; Kwon TH; Kim DH; Yang MS; Jang YS
Mol Cells; 1998 Oct; 8(5):585-93. PubMed ID: 9856346
[TBL] [Abstract][Full Text] [Related]
2. High Epstein-Barr Virus Load and Genomic Diversity Are Associated with Generation of gp350-Specific Neutralizing Antibodies following Acute Infectious Mononucleosis.
Weiss ER; Alter G; Ogembo JG; Henderson JL; Tabak B; Bakiş Y; Somasundaran M; Garber M; Selin L; Luzuriaga K
J Virol; 2017 Jan; 91(1):. PubMed ID: 27733645
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Epstein-Barr virus (EBV) release from P3HR-1 and B95-8 cell lines by monoclonal antibodies to EBV membrane antigen gp350/220.
Sairenji T; Bertoni G; Medveczky MM; Medveczky PG; Nguyen QV; Humphreys RE
J Virol; 1988 Aug; 62(8):2614-21. PubMed ID: 2839689
[TBL] [Abstract][Full Text] [Related]
4. An Epstein-Barr virus isolated from a lymphoblastoid cell line has a 16-kilobase-pair deletion which includes gp350 and the Epstein-Barr virus nuclear antigen 3A.
Lee W; Hwang YH; Lee SK; Subramanian C; Robertson ES
J Virol; 2001 Sep; 75(18):8556-68. PubMed ID: 11507201
[TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes.
Sample J; Young L; Martin B; Chatman T; Kieff E; Rickinson A; Kieff E
J Virol; 1990 Sep; 64(9):4084-92. PubMed ID: 2166806
[TBL] [Abstract][Full Text] [Related]
6. Sequence variation of EBNA2 of Epstein-Barr virus isolates from Korea.
Shim YS; Kim CW; Lee WK
Mol Cells; 1998 Apr; 8(2):226-32. PubMed ID: 9638656
[TBL] [Abstract][Full Text] [Related]
7. The Epstein-Barr virus candidate vaccine antigen gp340/220 is highly conserved between virus types A and B.
Lees JF; Arrand JE; Pepper SD; Stewart JP; Mackett M; Arrand JR
Virology; 1993 Aug; 195(2):578-86. PubMed ID: 8393237
[TBL] [Abstract][Full Text] [Related]
8. Nucleotide sequences and functions of the Epstein-Barr virus latent membrane protein 1 genes isolated from salivary gland lymphoepithelial carcinomas.
Jen KY; Higuchi M; Cheng J; Li J; Wu LY; Li YF; Lin HL; Chen Z; Gurtsevitch V; Fujii M; Saku T
Virus Genes; 2005 Mar; 30(2):223-35. PubMed ID: 15744579
[TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr virus (EBV) glycoprotein gp350 expressed on transfected cells resistant to natural killer cell activity serves as a target antigen for EBV-specific antibody-dependent cellular cytotoxicity.
Khyatti M; Patel PC; Stefanescu I; Menezes J
J Virol; 1991 Feb; 65(2):996-1001. PubMed ID: 1846213
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr virus nuclear antigen 2 activates transcription of the terminal protein gene.
Zimber-Strobl U; Suentzenich KO; Laux G; Eick D; Cordier M; Calender A; Billaud M; Lenoir GM; Bornkamm GW
J Virol; 1991 Jan; 65(1):415-23. PubMed ID: 1845900
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus types 1 and 2 have nearly identical LMP-1 transforming genes.
Sample J; Kieff EF; Kieff ED
J Gen Virol; 1994 Oct; 75 ( Pt 10)():2741-6. PubMed ID: 7931160
[TBL] [Abstract][Full Text] [Related]
12. DNA-mediated immunization of glycoprotein 350 of Epstein-Barr virus induces the effective humoral and cellular immune responses against the antigen.
Jung S; Chung YK; Chang SH; Kim J; Kim HR; Jang HS; Lee JC; Chung GH; Jang YS
Mol Cells; 2001 Aug; 12(1):41-9. PubMed ID: 11561729
[TBL] [Abstract][Full Text] [Related]
13. Binding of the endogenously expressed Epstein-Barr virus (EBV) envelope glycoprotein gp350 with the viral receptor masks the major EBV-neutralizing epitope and affects gp350-specific ADCC.
Khyatti M; Ahmad A; Blagdon M; Frade R; Menezes J
J Leukoc Biol; 1998 Aug; 64(2):192-7. PubMed ID: 9715258
[TBL] [Abstract][Full Text] [Related]
14. Peptides designed to spatially depict the Epstein-Barr virus major virion glycoprotein gp350 neutralization epitope elicit antibodies that block virus-neutralizing antibody 72A1 interaction with the native gp350 molecule.
Tanner JE; Coinçon M; Leblond V; Hu J; Fang JM; Sygusch J; Alfieri C
J Virol; 2015 May; 89(9):4932-41. PubMed ID: 25694592
[TBL] [Abstract][Full Text] [Related]
15. Recombinant Epstein-Barr virus glycoprotein 350 as a serological antigen.
Persson Berg L; Thomsson E; Hasi G; Bäckström M; Bergström T
J Virol Methods; 2020 Oct; 284():113927. PubMed ID: 32650039
[TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr Virus gp350 Can Functionally Replace the Rhesus Lymphocryptovirus Major Membrane Glycoprotein and Does Not Restrict Infection of Rhesus Macaques.
Herrman M; Mühe J; Quink C; Wang F
J Virol; 2016 Feb; 90(3):1222-30. PubMed ID: 26559839
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus latent membrane protein-1 oncogene deletions: correlations with malignancy in Epstein-Barr virus--associated lymphoproliferative disorders and malignant lymphomas.
Kingma DW; Weiss WB; Jaffe ES; Kumar S; Frekko K; Raffeld M
Blood; 1996 Jul; 88(1):242-51. PubMed ID: 8704180
[TBL] [Abstract][Full Text] [Related]
18. Marked, transient inhibition of expression of the Epstein-Barr virus latent membrane protein gene in Burkitt's lymphoma cell lines by electroporation.
Gahn TA; Sugden B
J Virol; 1993 Nov; 67(11):6379-86. PubMed ID: 8411339
[TBL] [Abstract][Full Text] [Related]
19. Establishment and characterization of Epstein-Barr virus gp350-expressing transfected human lymphoid (Raji) cell clones.
Khyatti M; Patel PC; Menezes J
Int J Cancer; 1991 Jun; 48(4):591-7. PubMed ID: 1646179
[TBL] [Abstract][Full Text] [Related]
20. Identification of multiple potent neutralizing and non-neutralizing antibodies against Epstein-Barr virus gp350 protein with potential for clinical application and as reagents for mapping immunodominant epitopes.
Mutsvunguma LZ; Rodriguez E; Escalante GM; Muniraju M; Williams JC; Warden C; Qin H; Wang J; Wu X; Barasa A; Mulama DH; Mwangi W; Ogembo JG
Virology; 2019 Oct; 536():1-15. PubMed ID: 31377598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
